Clinical trial
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
NCT03063632 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 14, 2017
- Completion date
- March 14, 2023
- Enrollment
- 28 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic myxoid liposarcoma, metastatic round cell liposarcoma, metastatic synovial sarcoma, recurrent mycosis fungoides and sezary syndrome, refractory mycosis fungoides and sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v7, stage ii mycosis fungoides and sezary syndrome ajcc v7, stage iia mycosis fungoides and sezary syndrome ajcc v7, stage iib mycosis fungoides and sezary syndrome ajcc v7, stage iii mycosis fungoides and sezary syndrome ajcc v7, stage iiia mycosis fungoides and sezary syndrome ajcc v7, stage iiib mycosis fungoides and sezary syndrome ajcc v7, stage iv mycosis fungoides and sezary syndrome ajcc v7, stage iva mycosis fungoides and sezary syndrome ajcc v7, stage ivb mycosis fungoides and sezary syndrome ajcc v7, unresectable synovial sarcoma